At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 73 enrolled
Drug / intervention
Propofol +1 moredrug
Likely dose
Propofol 0.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
In Brief
A Phase 4 clinical trial evaluating Propofol and Methohexital for Atrial Fibrillation and Atrial Flutter. Completed, enrolled 73 participants across 1 site.
Detailed Summary
A randomized, open-blinded, prospective study to evaluate the timeliness and safety of direct current cardioversion (DCCV) when using methohexital when compared to the more often used propofol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Atrial Flutter
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartApr 2020
Primary CompletionSep 2022
TodayJul 2026
First PostedDec 5, 2019
Enrollment StartApr 29, 2020
Primary CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.6 years ago
Interventions
Propofoldrug
Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
Methohexitaldrug
Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved